-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Does Patient Fitness Play a Role in Determining First-Line Treatment for AML

Program: Education Program
Session: Acute Myeloid Leukemia - So Many Treatment Options; How Do You Decide?
Hematology Disease Topics & Pathways:
AML, Biological, therapy sequence, Diseases, Therapies, Combinations, Myeloid Malignancies
Monday, December 7, 2020, 6:55 AM-7:00 AM

Jacqueline S. Garcia, MD

DFCI, Boston, MA

Disclosures: Garcia: Pfizer: Other; Genentech: Other; Lilly: Other; AbbVie: Other; AbbVie: Consultancy.

OffLabel Disclosure: Data from recent ASH 2019 meeting will be included

Previous Presentation | Next Presentation >>